PeerView Internal Medicine CME/CNE/CPE Audio Podcast

Latest Episodes:

Seth S. Martin, MD, MHS, FACC, FAHA, FASPC - Medicine in Motion: Smarter Approaches for Diagnosing HoFH Mar 10, 2023

Show notes

Go online to PeerView.com/BPX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While homozygous familial hypercholesterolemia (HoFH) is associated with development of atherosclerotic cardiovascular disease in childhood, early recognition and treatment of this inherited disease can improve outcomes for patients. In this animated activity provided by PeerView in collaboration with the Family Heart Foundation, a cardiologist describes the impact of this rare disease on patients and their families, presents strategies for recognizing signs and symptoms of HoFH, and reviews guidelines for genetic screening and referral of patients and their families to appropriate experts and resources for support. Additionally, two patients share their experiences of living with HoFH. Upon completion of this activity, participants should be better able to: Describe the consequences of undiagnosed and untreated HoFH from the patient’s perspective; Distinguish hallmark signs, symptoms, and family history differentiating HoFH from other disorders; and Employ current guidelines and support resources to direct patients with suspected HoFH to appropriately qualified care providers.

Ravin Ratan, MD, M.Ed - Addressing Key Questions About the Latest Diagnostic and Therapeutic Advances in Desmoid Tumors Mar 10, 2023

Show notes

Go online to PeerView.com/YNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Desmoid tumors are rare but aggressive soft-tissue tumors characterized by locally invasive growth, significant morbidity, and a high rate of recurrence. Considering that they are so rare, there are many challenges related to their recognition and establishment of an accurate diagnosis, and referral to a specialist is essential. Effective therapies have been lacking, but a number of systemic and local therapy options have been assessed in recent trials, with mixed results. Gamma secretase inhibitors are among the most recent promising, rational therapies for desmoid tumors that may transform the management of this disease. Given the transition of care from surgical approaches to more conservative strategies, the emergence of new systemic therapies, and the increasing importance of multidisciplinary coordination of care, there is an urgent need to address key questions and nuances related to modern treatment of patients with desmoid tumors. This educational program comprises a series of short, focused educational modules that hone in on some of the key questions in the diagnosis and treatment of desmoid tumors. Experts provide an update on the evolving evidence base for new and emerging therapies, and offer practical, case-based guidance for the multidisciplinary care team to help facilitate the application of recent advances to practice with the goal of improving patient care and outcomes. Patient perspectives and experiences are also integrated into the activity to highlight the importance of their education and engagement in care decisions. Upon completion of this activity, participants should be better able to: Characterize the epidemiology, predisposing factors, molecular pathogenesis, and clinical characteristics of desmoid tumors; Implement validated strategies that harness multidisciplinary team-based approaches for rapid recognition and accurate diagnosis of desmoid tumors; and Incorporate novel therapeutic approaches, including novel gamma-secretase inhibitors, into practice in the management of patients with desmoid tumors, taking into account the latest evidence, recommendations, and patient needs and preferences.

Seth S. Martin, MD, MHS, FACC, FAHA, FASPC - Medicine in Motion: Smart Approaches for Treating HoFH Mar 03, 2023

Show notes

Go online to PeerView.com/BNB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert on homozygous familial hypercholesterolemia (HoFH) discusses the latest data for novel lipid-lowering therapies and offers strategies for individualizing treatment regimens to improve outcomes for patients with HoFH. Upon completion of this activity, participants should be better able to: Apply standards of care to initiate and escalate lipid-lowering therapies in patients with HoFH; Distinguish the therapeutic characteristics of recently approved HoFH therapies according to their mechanisms of action; and Evaluate the benefits and limitations of approved HoFH therapies to individualize patient care.

Marwan Sabbagh, MD, FAAN - Gearing Up for Plasma Biomarkers in the Clinic: Real-World Strategies to Facilitate the Timely and Accurate Neuropathological Diagnosis of Alzheimer’s Disease Mar 01, 2023

Show notes

Go online to PeerView.com/DEC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Alzheimer’s disease (AD) is a devastating yet highly prevalent condition, affecting 10% of people aged 65 years and older and increasing in prevalence as the population ages. Recent advances in disease-modifying therapies have allowed for the possibility of reductions in disease progression and improved patient outcomes. Significant advances have also been made in identifying and testing biomarkers for AD that may aid in the early diagnosis of disease, facilitate patient selection for treatment, and monitor therapeutic response. In this activity, based on a recent live event, a panel of expert faculty provide training in the appropriate integration of validated and emerging cerebrospinal fluid (CSF) and plasma biomarkers into the AD diagnostic workup to identify early-stage AD in symptomatic patients. The faculty utilize a case-based approach to model the application and interpretation of fluid biomarkers in clinical practice, as well as highlight advantages and limitations associated with currently available and emerging CSF and plasma biomarkers. Upon completion of this activity, participants should be better able to: Apply validated fluid biomarkers to facilitate a timely neuropathological diagnosis of AD in symptomatic patients; Describe the limitations and advantages associated with currently available and emerging fluid diagnostics; and Integrate emerging plasma biomarkers into the diagnostic workup through appropriate application and accurate interpretation to improve early diagnosis and precision management of AD

Nasser Altorki, MD, Jonathan D. Spicer, MD, PhD, FRCSC - Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLC: How to Modernize Best Practices Based on New Evidence and Better Multidisciplinary Alliances Mar 01, 2023

Show notes

Go online to PeerView.com/YRK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The immunotherapy revolution has swiftly expanded from advanced lung cancer to the early-stage, resectable, curative-intent setting, and it is radically transforming the standards of care for stage I-III resectable NSCLC. Immunotherapies are now approved in both adjuvant and neoadjuvant settings, and ongoing trials are expected to propel more immunotherapy-based options into early-stage disease settings as well as clarify the best perioperative approaches. What do these developments mean for thoracic surgeons and other members of the multidisciplinary lung cancer care team? How should best practices and standards of care be modernized? What new workflows need to be established to guide individualized treatment selection and make the most of new immunotherapy options to reduce the risk of recurrence and increase the possibility of cure for more patients? This PeerView educational activity, based on a recent live symposium, brings together top experts to answer these questions. The faculty panel discusses new, practice-changing evidence, implications and applicability of these advances to practice, and how to best facilitate the incorporation of perioperative immunotherapy into new standards of care to improve outcomes and quality of life for patients with resectable NSCLC. Upon completion of this activity, participants should be better able to: Analyze the current evidence supporting the use of neoadjuvant and adjuvant immunotherapy approaches in stage I-III NSCLC, including the biologic and mechanistic rationale, novel endpoints, and data from key clinical trials; Identify patients with resectable NSCLC who are candidates for perioperative immunotherapy; and Implement neoadjuvant and/or adjuvant immunotherapy as part of individualized treatment plans for patients with resectable stage I-III NSCLC based on all the relevant factors, effective multidisciplinary collaboration, and shared decision-making

Jessica Donington, MD, Catherine Shu, MD - EGFR-Targeted Therapy for Early-Stage NSCLC: What Thoracic Surgeons Need to Know Mar 01, 2023

Show notes

Go online to PeerView.com/GQW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with early-stage lung cancer frequently experience disease recurrence within 1 year of receiving curative-intent surgery, representing a significant unmet medical need. Individualized management of patients with NSCLC is based on a number of considerations, including the molecular profile of the patient’s tumor and the benefits and limitations of therapeutic options in the context of the latest evidence. Continued advances with targeted therapies have sparked substantial interest in expanding their use into earlier disease settings, and adjuvant EGFR-targeted therapy has demonstrated remarkable efficacy in early-stage NSCLC, leading to the first regulatory approval of osimertinib as adjuvant therapy after resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations. In addition, results from studies in the neoadjuvant setting are emerging now, as perioperative use of EGFR-targeted therapy continues to demonstrate improved outcomes. Thoracic surgeons are key members of the multidisciplinary care team, playing an essential role in collaborating and coordinating with other specialists to determine the best treatment plan, including incorporating EGFR-targeted therapy into multimodal management strategies. This PeerView educational activity, based on a recent live symposium, focuses on the latest clinical evidence supporting the use of EGFR-targeted therapy in perioperative settings and provides practical guidance for optimally integrating targeted therapies in practice or clinical trials. Multidisciplinary discussions on the latest practice-changing data highlight important implications of utilizing EGFR-targeted therapy as part of multimodal treatment for surgeons and the broader lung cancer care team. Upon completion of this activity, participants should be better able to: Discuss the role of EGFR mutations in NSCLC, advances in EGFR-targeted therapy in earlier disease settings, and the importance of identifying patients who might benefit from these therapies in perioperative settings; Identify patients with early-stage resectable NSCLC who are candidates for adjuvant EGFR-targeted therapy or investigational targeted approaches according to the latest evidence and guidelines; and Implement multidisciplinary and patient-centric strategies to integrate EGFR-targeted therapy into multimodal treatment plans for eligible patients with early-stage resectable NSCLC

Sanjay R. Bhagani, BSc (Hons), MB ChB, FRCP - Improving Outcomes for Hospitalized Patients with COVID-19: Expert Perspectives on Incorporating the Latest Guidelines and Evidence Into Clinical Practice Mar 01, 2023

Show notes

Go online to PeerView.com/SRU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the availability of testing, vaccines, and treatments, COVID-19 remains a threat—no one can predict when a new strain might surface and many questions remain. The virus that causes COVID-19 is designated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the clinical spectrum of SARS-CoV-2 infection ranges from asymptomatic to critical and fatal illness. Most symptomatic infections are mild; however, a significant number of patients have severe disease requiring hospitalization. Hospitalization and death are more likely in high-risk populations, including older people, individuals with underlying medical problems, and those affected by systemic health and social inequities (ie, minorities, immigrant populations, people of low socioeconomic status, and the disabled). Therapies such as antiviral agents and monoclonal antibodies are available in the United States and Europe for the treatment of COVID-19; however, there are challenges with determining which hospitalized patients may be best suited for which treatment. In this activity, based on a recent live web broadcast, a panel of experts explores strategies to improve outcomes for COVID-19 in the hospital setting, with a focus on designing individualized treatment plans based on current guidelines, evolving evidence, and patient-specific factors. The panel also discusses how differences in drug access and treatment protocols impact the healthcare team in regards to providing individualized treatment programs for patients hospitalized with COVID-19. Upon completion of this activity, participants should be better able to: Assess patients with COVID-19 to make appropriate treatment recommendations based on disease severity; Differentiate therapies for COVID-19 based on the latest safety and efficacy data from clinical trials; Collaborate with the healthcare team to design timely and individualized treatment plans for hospitalized patients with COVID-19 disease based on current guidelines, evolving evidence, and patient-specific factors; and Discuss the clinical implications of prolonged/persistent viral replication in severe COVID-19

Loretta J. Nastoupil, MD - Innovation Now for Follicular Lymphoma: New Evidence for Immunotherapy, Targeted, and Chemo-Free Options Mar 01, 2023

Show notes

Go online to PeerView.com/SZT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on the latest evidence with immunotherapy, targeted agents, and chemo-free options for follicular lymphoma (FL)? Find out by accessing this activity, where an expert will interpret new evidence supporting the continued integration of bispecific antibodies, CAR-T cell therapy, EZH2 inhibitors, and PI3K inhibitors across multiple lines of therapy in relapsed/refractory FL. Throughout, the expert shares guidance on therapeutic sequencing, safety management, and the future use of innovative combination platforms. Don’t miss this important update from ASH! Upon completion of this activity, participants should be better able to: Summarize evidence surrounding targeted, epigenetic, and immunotherapy options for R/R FL; Integrate modern, evidence-based sequential treatment plans for R/R FL that include immunomodulatory drugs, targeted therapies, epigenetic agents, bispecific antibodies, and CAR-T constructs; and Manage the unique suite of adverse events associated with the use of novel therapeutics as sequential management options in R/R FL

John C. Byrd, MD - Taking the Next Steps With Next-Generation BTK Inhibitors in CLL, MCL, and DLBCL Mar 01, 2023

Show notes

Go online to PeerView.com/EVF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on the latest evidence with next-generation BTK inhibitors (BTKi) in CLL/SLL, MCL, and DLBCL from the 2022 ASH annual meeting? Find out in this new activity where two experts will interpret new findings supporting the integration of next-generation BTKi across multiple lines of therapy in B-cell cancers, while addressing practical safety considerations that may arise while patients are on therapy; additionally, the experts will provide their takes on how new science will drive future applications of BTKi in a range of B-cell cancer settings. Don’t miss this educational and informative activity! Upon completion of this activity, participants should be better able to: Cite updated evidence with BTKi-based strategies in CLL/SLL, including longer-term follow-up from pivotal trials, current guidelines, head-to-head data, and outcomes with novel BTK combination platforms; Summarize efficacy and safety findings supporting the use of BTKi options in aggressive lymphoma, including in R/R MCL and DLBCL; Select personalized therapy with BTKi in CLL based on current evidence, safety considerations, and patient and disease characteristics; and Integrate BTKi therapy into the management of aggressive lymphoma, including in patients with previously treated MCL or DLBCL

Marwan Sabbagh, MD, FAAN - Translating the Latest Research Advances Into Routine Care for Alzheimer’s Disease: Preparing Dementia Specialists With the Latest Strategies to Support Early Diagnosis and Comprehensive Care Mar 01, 2023

Show notes

Go online to PeerView.com/GAZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses strategies for optimizing the biomarker-based diagnosis of Alzheimer’s disease early in the disease course and the selection of appropriate patients who might benefit from novel disease-modifying therapies, as well as a comprehensive care model for the multidisciplinary management of patients with Alzheimer’s disease. Upon completion of this activity, participants should be better able to: Apply current and emerging diagnostic tools to optimize the biomarker-based diagnosis of AD early in the disease course; Select appropriate patients with AD who may benefit from novel disease-modifying therapies based on an understanding of their mechanisms of action, efficacy, and safety profiles; and Utilize a comprehensive care model to optimize the multidisciplinary management of patients with AD